Board of Directors Cite Progress on and Acceleration of 2.0 Strategy

Phunware 2.0 Supported by Strong Leadership Team,
Balance Sheet and Liquidity

Company Urges Stockholders to Vote “FOR” Chairperson Elliot Han on the WHITE Proxy Card

AUSTIN, Texas, Nov. 20, 2026 (GLOBE NEWSWIRE) — Phunware, Inc. (“Phunware” or the “Company”) (NASDAQ: PHUN), a mobile-first AI-enabled guest intelligence platform company focusing on hotels, resorts, health systems and other large complex properties, has filed its definitive proxy statement and today issued a letter from its Board of Directors (the “Board”) to stockholders ahead of the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”), which will be held virtually on December 17, 2026 at 11:00 a.m. Eastern Time.

The letter outlines the recommendation of the Board’s Special Committee on Election Matters for stockholders to re-elect Board Chairperson Elliot Han for another term as a Class II director, the Company’s progress and prospects under its 2.0 Strategy, and its responses to the proxy materials filed by Goldenwise Capital Group Limited (“Goldenwise”). Shareholders of record as of October 19, 2026, are entitled to vote at the Annual Meeting.

What You Need to Know Before You Vote.

At the December 17, 2026 Annual Meeting, stockholders will vote on a nominee to fill one Board seat. The Special Committee urges you to vote “FOR” Chairperson Elliot Han on the WHITE proxy card.

  • Mr. Han has played a key role in strengthening Phunware’s finances and leadership. He championed the approximately $104 million capital raise in 2024 that resolved liquidity challenges. As of September 30, 2026, Phunware held approximately $86.7 million in cash and cash equivalents, with no debt. Further, as Chairperson, led the appointment of Dmitry Kroshka as permanent CEO, ending a period of interim leadership.
  • Goldenwise has not made a convincing case. It has not made any proposals establishing how replacing Mr. Han would improve Phunware’s new strategy, customer acquisition, product commercialization, recurring revenue growth or other critical performance metrics. Stockholders deserve a clear explanation of how Goldenwise’s nominee would improve the Company and its prospects.
  • Mr. Ding’s disclosure record raises serious questions. He answered “No” when asked whether he had been involved in any prior proceedings involving allegations of a breach of fiduciary duty or similar conduct, despite being named in a 2020 lawsuit alleging professional negligence and breach of fiduciary duty involving approximately $1.3 million in alleged investment losses. Separately, Goldenwise only provided more fullsome public disclosure of its short call and short put options after Phunware questioned the accuracy and completeness of these disclosures. Shareholders deserve complete and accurate information from Goldenwise as they are being asked to vote in favor of its nominee for the Board.
  • Ms. Zhang’s commercial ties and track record warrant scrutiny. Her firm, Trunity Partners, had a business relationship with Goldenwise in 2025, and she served alongside Mr. Ding on Moberg Pharma’s board for just under eight months, where she was not re-elected in May 2026. Her independence from Goldenwise and what relevant experience she would bring to Phunware’s Board deserve scrutiny.
  • An independent review concluded Mr. Han is the stronger choice. A Special Committee of independent directors, with Mr. Han recused, evaluated both candidates. He brings a wealth of relevant public-market leadership experience, capital-markets and finance expertise, legal training, governance experience as Audit Committee chair and audit committee financial expert, and a hands-on role shaping and implementing the Phunware 2.0 Strategy. Ms. Zhang’s background is not additive to the Board’s aggregate skillset. Mr. Han’s extensive knowledge of Phunware 2.0 supports continuity as the Company works to convert its investments into signed customer agreements and recurring revenues.

How to Vote

Vote FOR Elliot Han only, on the WHITE proxy card, by Internet, telephone or mail, by 11:59 p.m. Eastern Time on December 16, 2026. Discard any GOLD card: a later-dated GOLD card cancels your WHITE vote. Questions? Call Alliance Advisors toll-free at 1-888-244-0487.

Letter to Stockholders

Dear Stockholders:

We believe Phunware is at a critical point in its evolution and transition. The Phunware Board and management team have been strengthened, a new vision and strategy referred to as “Phunware 2.0” is now being implemented, and the related hospitality and healthcare intelligence platforms, modules and products are in development. We are very focused on finalizing and adopting our 2027 operating plan and budget for Phunware 2.0 and completing and converting our 2.0 Strategy into revenues and enterprise value for our stockholders. We believe that continuity and uninterrupted execution at the top are very important to completing the 2.0 Strategy and ensuring those investments turn into growth for stockholders.

At Phunware’s 2026 Annual Meeting on December 17, 2026, stockholders will elect one Class II director to a three-year term. The Board’s nominee is Chairperson Elliot Han. Goldenwise Capital Group Limited, a Hong Kong-based investment manager led by its founder Mr. Huakun Richard Ding, has put forward Ms. Xuan Zhang in opposition to Mr. Han.

Stockholders should carefully examine the record, relationships, and objectives of anyone seeking Board influence. Mr. Ding began engaging with Phunware only this year. Against that limited history (and as discussed in more detail below), the discrepancy in his signed director questionnaire, Ms. Zhang’s commercial ties to Goldenwise and Mr. Ding, and the absence of a specific operating plan or alternative strategy presented by Mr. Ding warrant heightened scrutiny before stockholders entrust his nominee with a seat on the Board. In our view, Goldenwise has been far more specific about the Board influence it wants than the value its nominee would create for Phunware and its stockholders.

The question is not whether Ms. Zhang has useful qualifications: the question is whether replacing Mr. Han would make the Board stronger and improve Phunware and its prospects. The Board’s Special Committee on Election Matters concluded it would not, by concluding, among other items, that:

Mr. Han has delivered. He championed a capital raising strategy that resolved near-term liquidity challenges in 2024; he led the Board’s appointment of a permanent CEO, ending a period of interim leadership, paired with the installment of fuller executive bench; and he strongly supported and provided oversight and guidance on a near daily basis for implementation of our new Phunware 2.0 Strategy. Mr. Han went above and beyond to use his first term to lay a strong foundation for future growth, and his renomination ensures the Board can build on it without disruption.

Goldenwise has offered no plan. Despite repeated Board invitations to do so, Goldenwise failed to present any other specific operating plan or alternative strategy for Phunware. Goldenwise now appears to support the 2.0 Strategy, and require an operating plan and budget, with spending requirements and dated milestones – all of which the Board intends to do for 2027.

The Special Committee recommends that you vote FOR Chairperson Elliot Han on the WHITE proxy card.

Why the Special Committee Recommends Elliot Han

Mr. Han has served on the Board as an independent director since January 2024 and as Chairperson since October 2025. He also chairs the Audit Committee and is designated an audit committee financial expert. His experience includes senior roles at Cantor Fitzgerald, the New York Stock Exchange, and Goldman Sachs, in addition to practicing corporate law at Freshfields. He is currently the Chief Investment Officer of C1 Fund Inc., a publicly traded closed-end investment fund, and a Partner at PGP Capital Advisors.

For stockholders, we believe the most important qualifications for a director at Phunware are:

  • Direct knowledge of Phunware’s business, technology, and 2.0 Strategy to challenge and support management and evaluate execution.
  • Financial and transactional expertise to oversee funding decisions, capital allocation, and inorganic growth.
  • Governance and leadership experience to support effective oversight and transparency as the Company moves forward.

As a Board member, Mr. Han advocated for and facilitated Phunware’s completion and utilization of its 2024 at-the-market equity financing program, through which the Company raised approximately $104 million. This capital addressed significant near-term liquidity needs and materially strengthened Phunware’s balance sheet and reduced debt, providing Phunware with the financial flexibility to pursue a strategic reset, adapt to macro headwinds, invest in strategy and product development, and evaluate inorganic growth opportunities. Since the commencement of his Board chairmanship in October 2025, Mr. Han helped develop and advance the Company’s strategic pivot to Phunware 2.0, pushing Phunware from a legacy wayfinding and enterprise mobile development company to the AI-powered Guest Intelligence Platform phase and enabling execution of the strategy by helping appoint Dmitry Kroshka as permanent CEO and assembling an experienced product, marketing, sales, and finance team of employees and senior advisors to implement Phunware 2.0. He sharpened the Company’s focus and promoted operating discipline around defined platforms and related modules, products and customer propositions.

Importantly, Mr. Han’s contributions to the Board and the Company extend beyond financing and strategy. He has chaired the Compensation Committee, during which time he helped oversee CEO succession and disciplined executive and employee incentives, including conserving capital and aligning leadership incentives with the Company’s turnaround and performance. He has chaired the Audit Committee, during which he oversaw financial reporting, external audits, compliance, and risk controls. He has also led the Strategic Transactions Committee’s oversight of potential acquisitions and capital deployment. Mr. Han demonstrated leadership during a transformational turnaround period, navigating the Company through organizational changes and overseeing the Company’s responses to litigation matters while limiting management distraction. His level of commitment has been demonstrated through his attendance at all Board and committee meetings, substantive travel, preparation, participation, and substantial availability for Company matters.

To ensure an independent evaluation of the director candidates, the Board established a Special Committee on Election Matters, composed of independent directors Quyen Du and Ed Lu; Mr. Han was recused from such deliberations. After weighing the qualifications and fit of all candidates, the Board’s collective capabilities, and the Company’s current and foreseeable needs, the Special Committee determined that Mr. Han’s demonstrated contributions, independent judgment, and unique combination of capital markets, technology investments, legal, corporate finance, and transactional expertise, together with his governance and leadership experience and deep knowledge of Phunware and the 2.0 Strategy, made him the clear best choice. Continuity alone does not entitle a director to re-election, but it is extremely valuable at present because of Mr. Han’s specific experience, institutional knowledge of Phunware’s business, operating and management history, demonstrated leadership through periods of market and organizational transitions, oversight, and complementary fit as Chairperson and a member of the Board.

Why Replacing Mr. Han with Goldenwise’s Nominee Would Not Benefit Stockholders

The Special Committee is aware of Ms. Zhang’s qualifications and experience in investment management, capital allocation, and strategic advisory work. However, the materials provided and reviewed did not establish a sustained record of experience which the Board is focused on, including direct responsibility for commercial scaling, go-to-market experience, deep domain knowledge in hospitality and healthcare, AI, platform launches, executive management and operating leadership, and post-acquisition integration experience. In light of the Company’s needs and existing Board composition, these were and are important considerations for new directors as Phunware moves its AI-powered Guest Intelligence Platform and other components of Phunware 2.0 towards commercialization.

Ms. Zhang’s known public-company board experience consisted principally of approximately eight months on the board of Moberg Pharma, a company listed in Sweden. Although proposed for re-election, Ms. Zhang did not retain her seat at Moberg’s May 21, 2026 annual meeting, when stockholders elected an alternative slate that excluded her. Ms. Zhang’s director questionnaire described her experience with investment and oversight frameworks, but the Committee did not find and Goldenwise has not shown sufficiently specific support for the proposition that her background and experience would improve Phunware’s product-market fit, technology expertise, commercialization milestones, or decisions about potential operating decisions or strategic alternatives. Also, her disclosed biography does not identify service on the board of a U.S.-listed company, and Goldenwise has not shown how her experience would strengthen the Board’s existing expertise in U.S. public-company governance and financing or in Phunware’s business.

The question for stockholders is not whether Ms. Zhang possesses useful professional qualifications. It is whether replacing Mr. Han with Ms. Zhang would strengthen the Board or improve the Company or its prospects, in particular the Company’s implementation of its 2.0 Strategy. The Committee concluded that her investment expertise and advisory background did not establish a sufficiently differentiated contribution in key areas of interest to the Board to offset the loss of Mr. Han’s demonstrated capital-markets, corporate legal, transaction, governance, and Phunware-specific experience or meet the anticipated operational needs in the Company’s next phase in the 2.0 Strategy. As such, the Committee supported and recommended Mr. Han’s renomination.

Progress Under Phunware’s 2.0 Strategy

Since February 2025, two new independent directors joined the Board: Quyen Du, formerly Head of Corporate Strategy and Development of Condé Nast, and Ed Lu, Chief Financial Officer and Chief Operating Officer of Fandom. In May 2026, under Mr. Han’s Chairmanship, the Board appointed Dmitry Kroshka as Chief Executive Officer, ending a period of interim CEO leadership and establishing a clear direction for the Company’s 2.0 Strategy.

Under the 2.0 Strategy, Phunware is bringing together its mobile, location-aware, and customer-engagement capabilities with AI to develop a shared intelligence platform for hospitality, healthcare, and other complex property verticals. We are excited about Phunware’s prospects under the 2.0 Strategy and believe it will be very beneficial to building long-term value for stockholders. Please see our stockholder letter released in October 2026, which can be accessed here, and our investor deck also posted in October 2026, which can be accessed here, for more information and detail on our 2.0 Strategy and recent milestones.

We have ample liquidity to implement and execute our 2.0 Strategy, including through inorganic growth opportunities. As of September 30, 2026, Phunware held approximately $86.7 million in cash and cash equivalents with no debt.

Your Board and management team remain focused on disciplined technology and data development, product sales and revenues, capital allocation and inorganic growth opportunities, demonstrating commercial progress, and keeping stockholders informed as we execute the 2.0 Strategy.

Goldenwise Has Not Presented a Specific Operating Plan or Alternative Strategy

We welcome stockholder input and recognize that every investor has the right to question our performance, strategy, and governance. However, a request for Board representation should be supported by a clear explanation of what would change and how stockholders would benefit.

Goldenwise has not proposed a specific operating plan or alternative strategy for Phunware’s business or growth or explained how its nominee would improve Phunware or its execution of the 2.0 Strategy. The Goldenwise materials provided so far are long on criticism and short on constructive substance. The Company invited Mr. Ding, on multiple occasions, to present specific proposals on product, strategy, acquisitions, capital allocation, and stockholder communications. To date, he has failed to present any such proposals. This is consistent with the pattern Goldenwise has shown throughout: demand Board representation, focus on broad generic themes that Phunware is already addressing, fail to engage on substance and details, and then accuse the Company of stonewalling.

Goldenwise’s demands for Board representation have shifted considerably. In April 2026, Mr. Ding urged the Board to add two or three directors. In June 2026, he proposed expanding the Board from three (3) to six (6) members and subsequently submitted four potential candidates, including himself. Goldenwise is now seeking to have one nominee elected to fill the single available seat. The number of seats sought has changed, but the demand for Board influence, without a specific operating plan or alternative strategy, reflects, in our view, an unfocused and undeveloped proposal. Stockholders should expect a clear, focused and developed plan and greater conviction from someone seeking to reshape the Board. As noted above, there is no need to reshape the Board to implement Phunware 2.0 with appropriate operating plan and budget: that will occur, and we welcome shareholder input on implementation of the adopted plan.

On broad themes and engagement, Goldenwise’s own proxy materials document discussions with the Company’s legal team on April 14, 2026, and meetings with the Board on May 15 and June 30, 2026, regarding those themes. The Company also prepared and offered to enter into a confidentiality agreement with Goldenwise and Mr. Ding to enable deeper discussions that could involve nonpublic information. Goldenwise’s proxy states that Mr. Ding declined on June 5, because the agreement might restrict further stock purchases or otherwise disadvantage stockholders. Confidentiality agreements of this kind are customary when an investor seeks access to nonpublic information. They protect all stockholders by ensuring that no single investor has access to information that other investors do not have when making trading decisions. Goldenwise’s later disclosures of short call and short put positions alongside its shareholdings reinforced, in the Company’s view, the importance of those protections. If Goldenwise and Mr. Ding signed the agreement, the Company believes the parties would have had a fuller and more meaningful dialogue.

Stockholders Deserve a Full and Accurate Context

Goldenwise’s criticisms of director compensation and leadership changes omit important details and context.

The August 2026 equity awards Goldenwise cites were granted under Phunware’s Outside Director Compensation Policy, which was adopted by the Board under a prior Chairperson who is no longer on the Board in June 2024 and benchmarked to market practice, well before Goldenwise began accumulating its reported position. The policy provides for non-discretionary annual director restricted stock unit awards with a stated value of $150,000. Goldenwise also mischaracterizes these awards by suggesting that these awards for Board service are discretionary, which they are not, and that these awards should have had an acquisition cost, which would be extremely uncommon and inconsistent with market practice.

Board compensation is also now paid in arrears rather than in advance for quarterly board services rendered, which further aligns directors with stockholders. Given Phunware’s internal resource challenges and the critical issues that it has been facing, Mr. Han and the other directors have consistently committed more time than is customary throughout their respective Board tenures.

On leadership changes, two of the three CEO transitions Goldenwise highlights occurred before Mr. Han became Chairperson in October 2025. The last two interim CEOs were appointed under the leadership of the above referenced prior Chairperson. The most recent CEO transition was the Board’s appointment of Dmitry Kroshka as permanent Chief Executive Officer in May 2026, under the leadership of Mr. Han as Chairperson, ending the interim leadership period. These distinctions matter when assessing the current Board leadership.

The Committee Also Considered Ms. Zhang’s Ties to Mr. Ding

The Special Committee considered Ms. Zhang’s professional and business relationships with Mr. Ding, including their overlapping service on the Moberg Pharma board and a sub-advisory arrangement between Ms. Zhang’s firm, Trunity Partners, and Goldenwise during 2025. These relationships require scrutiny when assessing whether she would as a Board member exercise judgment independently of the investor sponsoring her candidacy. Calling a nominee independent does not make her commercial ties to that investor irrelevant.

Mr. Ding’s record at Moberg Pharma also warrants scrutiny. Between August 13 and October 5, 2026, while remaining a director, he reported sales totaling 988,607 Moberg shares. Phunware stockholders should not confuse a demand for Board influence with a commitment to remain invested for the long term. By contrast, no current Phunware director has sold Phunware shares during his or her Board tenure (other than to cover taxes upon vesting of shares).

Goldenwise Demands Transparency While Its Own Record Raises Serious Questions

Goldenwise has called for greater transparency from the Board option positions, while its own disclosures to the Company leave serious gaps. In 2020 a complaint was filed in federal court naming Mr. Ding and Goldenwise Capital Management, Inc. as defendants, alleging professional negligence and breach of fiduciary duty arising from approximately $1.3 million in alleged investment losses over several days. This complaint is a matter of public record. Yet Mr. Ding submitted a signed director questionnaire to the Board (at a time when he was proposing himself and three (3) others for Board seats) answering “No” to a direct question asking whether, during the prior 10 years, he had been the subject of a legal proceeding involving breach of fiduciary duty, gross negligence, or similar conduct. In the Company’s view, this discrepancy raises questions about the completeness and accuracy of information provided to the Company in connection with the Goldenwise nominations. A demand for transparency by Goldenwise carries little weight without full candor from the person making it.

The disclosure concerns extend beyond the lawsuit. Mr. Ding’s signed questionnaire identified short call and short put options but provided insufficient detail to understand their terms and economic effect. Goldenwise’s July 10 and July 14 public filings did not describe those positions. Phunware publicly questioned these gaps on July 16. Four days later, Goldenwise added contract counts, strike prices, and expiration dates to its filing. Shareholders deserve an explanation for why fuller disclosure followed a public challenge from the Company. These positions also matter when assessing Mr. Ding’s claim of complete alignment with shareholders. Goldenwise’s October 20 filing disclosed short call options alongside long shares and short puts. Short calls can limit participation in a share price recovery above the strike price, while short puts can increase exposure to further declines. These arrangements can create different risks and rewards from those of shareholders who simply hold the stock. Before accepting Mr. Ding’s claim of complete alignment, shareholders deserve a full understanding of the financial interests behind his campaign.

Goldenwise May Seek Reimbursement for Its Campaign

Goldenwise estimates its solicitation costs at approximately $130,000 and stated that, if successful, it intends to seek reimbursement from Phunware, without submitting such reimbursement to a stockholder vote. Its campaign to reduce Company spending therefore comes with a potential bill for its own expenses.

Stockholders Have Significant Reason to be Cautious

The discrepancy in Mr. Ding’s director questionnaire, Ms. Zhang’s commercial ties to Goldenwise, and the absence of a specific operating plan or alternative strategy proposal, give stockholders significant reasons to be cautious and skeptical about entrusting Goldenwise’s nominee with a Board seat. Mr. Ding’s demand for influence should be tested against the accuracy of his own disclosures and the relevant experience and independence of his nominee. Goldenwise has given stockholders more reasons to question its campaign than to trust its nominee with a seat on the Board.

Stockholder Returns and the Case for Continuity

We recognize that Phunware’s recent share-price performance has been disappointing. We believe that as the Company implements the 2.0 Strategy the market will likely improve that performance. The Special Committee expressly considered stockholder returns in its assessment of Mr. Han, alongside the legacy business challenges, leadership transitions, and timing of the new strategy. Phunware 2.0 was approved in early 2026 and its broader leadership and advisory team was assembled in May 2026. The Committee nevertheless concluded that Mr. Han’s demonstrated contributions and relevant expertise make his continued service the best choice for Phunware stockholders.

We believe the current Board and management team have established a clear vision, strategy, and direction with Phunware 2.0 and that Mr. Han’s continued Board service is necessary to provide needed operational continuity, valuable oversight, and support to management as the Company steers Phunware forward from its legacy businesses to implement and execute on the 2.0 Strategy. Goldenwise has not demonstrated that replacing him would strengthen this Board or improve the Company’s prospects.

For these reasons, the Special Committee recommends that stockholders vote “FOR” the re-election of Elliot Han on the WHITE proxy card at the 2026 Annual Meeting.

How to Vote

Phunware is using a universal proxy card, which lists the Board’s nominee and the Goldenwise nominee. Because only one director will be elected, please vote “FOR” only one nominee. Marking more than one will invalidate your vote on the election of the Class II director.

  • Vote “FOR” Elliot Han on the WHITE proxy card or WHITE voting instruction form, by Internet, telephone or mail, following the instructions on the card. Internet votes by stockholders of record must be received by 11:59 p.m. Eastern Time on December 16, 2026.
  • Discard any GOLD proxy card sent by Goldenwise. Signing and returning a later dated GOLD proxy card can revoke an earlier WHITE proxy card, even if you vote “WITHHOLD” on the GOLD card.
  • If you have already returned a GOLD card, you can change your vote by submitting a later-dated WHITE proxy card. Only your latest-dated proxy will be counted.
  • Even if you wish to vote for the Goldenwise nominee, the Board recommends that you use the WHITE proxy card to do so.
  • If you hold shares in more than one account, please vote each WHITE proxy card or voting instruction form you receive.

The Board also recommends that you vote “FOR” the ratification of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for 2026, “FOR” the advisory vote to approve named executive officer compensation, and for “THREE YEARS” on the frequency of future advisory votes on executive compensation.

To attend the virtual 2026 Annual Meeting of Stockholders, stockholders must register in advance at www.cesonlineservices.com/phun26_vm by 11:00 a.m. Eastern Time on December 16, 2026.

The 2.0 Strategy is in its first year. We ask for your support in giving that strategy the continuity it needs by voting “FOR” Elliot Han on the WHITE proxy card today.

Thank you for your continued support and investment in Phunware.

Sincerely,

The Special Committee on Election Matters of the Phunware Board of Directors

YOUR VOTE IS IMPORTANT

If you have any questions or need assistance voting your shares, please contact the Company’s proxy solicitor:

Alliance Advisors, LLC
150 Clove Road, Suite 400
Little Falls, NJ 07424
Toll-Free: 1-888-244-0487
Email: phun@allianceadvisors.com

About Phunware

Phunware, Inc. (NASDAQ: PHUN) is an enterprise software company building an AI-enabled Guest Intelligence Platform for operators of hotels, resorts, healthcare facilities and other complex properties. Its Phunware 2.0 strategy combines mobile engagement, proprietary location-aware technology and modular AI products to help operators improve guest and patient experiences, better understand on-property activity and identify new revenue opportunities.

For more information on Phunware, please visit www.phunware.com.

Safe Harbor / Forward-Looking Statements

This press release includes forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy and plans, our objectives for future operations, the development and commercial rollout of our Phunware 2.0 strategy and Guest Intelligence Platform, the performance and adoption of our AI Concierge, AI Itinerary Planner, Operator Console, and Location-Aware Data Layer capabilities, the expansion of our product offering into adjacent end markets, and the timing of upcoming investor and industry events, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” and similar expressions are intended to identify forward-looking statements.

The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments and their potential effects on us. These forward-looking statements involve risks, uncertainties, and other assumptions that may cause actual results to differ materially from those expressed or implied. These risks and uncertainties include, but are not limited to, those factors described under the heading “Risk Factors” in our filings with the SEC. We undertake no obligation to update any forward-looking statements.

By their nature, forward-looking statements involve risks and uncertainties. We caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from those expressed or implied by these forward-looking statements.

Important Additional Information and Where to Find It

The Company has filed with the SEC a definitive proxy statement on Schedule 14A and an accompanying WHITE proxy card in connection with its solicitation of proxies from the Company’s stockholders for the 2026 Annual Meeting of Stockholders. THE COMPANY’S STOCKHOLDERS ARE STRONGLY ENCOURAGED TO READ THE COMPANY’S DEFINITIVE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO), THE ACCOMPANYING WHITE PROXY CARD AND ANY OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY, BECAUSE THEY CONTAIN IMPORTANT INFORMATION. Stockholders may obtain copies of these documents free of charge at the SEC’s website at www.sec.gov, at www.proxydocs.com/PHUN and on the Company’s investor relations website at investors.phunware.com.

Participants in the Solicitation

The Company, its directors and certain of its executive officers and employees may be deemed participants in the solicitation of proxies from stockholders in connection with the matters to be considered at the 2026 Annual Meeting. Information regarding the direct and indirect interests, by security holdings or otherwise, of the persons who may, under the rules of the SEC, be considered participants in the solicitation of proxies from stockholders in connection with the 2026 Annual Meeting is included in the Company’s definitive proxy statement, filed with the SEC on November 2, 2026. To the extent that the holdings of the Company’s securities by its directors and executive officers have changed from those reported in the proxy statement for the 2026 Annual Meeting, such changes have been or will be reflected in filings on Forms 3, 4 or 5 with the SEC. These documents are available free of charge on the SEC’s website at www.sec.gov.

Investor Relations Contact:
Chris Tyson, Executive Vice President
MZ Group – MZ North America
949-491-8235
PHUN@mzgroup.us
www.mzgroup.us

SINGAPORE, Nov. 20, 2026 (GLOBE NEWSWIRE) — Phaos Technology Holdings (Cayman) Limited (NYSE American: POAS) (the “Company”) is correcting the statement about ongoing equity relationships in its September 18, 2026 press release concerning SG AB Venture Pte. Ltd. and TongHuai SG2 Enterprise Pte. Ltd., furnished as Exhibit 99.1 to the Company’s Form 6-K of the same date (SEC Accession No. 0001493152-26-043247).

The September 18 press release incorrectly stated that neither entity maintained an ongoing equity relationship with the Company. The cessation of common directorships did not end their shareholdings. Both entities held shares of the Company when the September 18 press release was issued and continue to hold shares as of the date of this release.

This release supersedes the September 18 press release only to the extent it stated or implied that the two entities no longer held shares of the Company. The correction does not make a new determination regarding either entity’s related-party status.

About Phaos Technology Holdings (Cayman) Limited

Phaos Technology Holdings (Cayman) Limited is headquartered in Singapore and has its roots in advanced microscopy. The Company is pursuing a strategic repositioning toward engineering, procurement and construction (“EPC”) to broaden its business beyond microscopy. The strategy remains under development, and implementation depends on the Company’s resources, capabilities and any required approvals. For more information, visit www.phaostech.com.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of applicable U.S. securities laws, including the Private Securities Litigation Reform Act of 1995, to the extent applicable. These statements include the Company’s plans for its strategic repositioning toward EPC. They are based on management’s current expectations and assumptions and do not guarantee future results. Actual results could differ materially due to risks and uncertainties, including financing constraints, difficulties implementing the EPC strategy and the availability of required approvals. Additional risks are described in the Company’s annual report on Form 20-F, as amended, and its other reports filed with or furnished to the U.S. Securities and Exchange Commission, available at www.sec.gov.

Readers should not place undue reliance on these statements. They speak only as of the date of this release, and the Company does not undertake to update them except as required by applicable law. The statements about historical and current shareholdings are not forward-looking.

No Offer or Solicitation

This release is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities.

Investor Relations Contact

Phaos Technology Holdings (Cayman) Limited
+65 6250 3877
ir@phaostech.com

Company estimates customers with three or more years of service are saving approximately 50% on solar-generated electricity compared with purchasing equivalent power from utilities

NEW PORT RICHEY, Fla., Nov. 20, 2026 (GLOBE NEWSWIRE) — Zeo Energy Corp. (Nasdaq: ZEO) (“Zeo,” “Zeo Energy,” or the “Company”), a provider of residential solar and commercial long-duration energy storage (“LDES”) solutions, today highlighted the long-term cost advantages of residential solar, with Company estimates indicating that customers who installed systems three or more years ago are saving an average of approximately 50% on solar-generated electricity compared with purchasing equivalent power from their local utilities at current rates.

“Our customers are seeing the long-term economic benefits of going solar,” said Tim Bridgewater, Chairman and CEO of Zeo Energy. “Many who installed systems three or more years ago are now paying roughly half what they would pay their utilities for the same electricity. We believe these savings demonstrate why residential solar remains an attractive option for homeowners looking to control their energy costs.”

Data from the U.S. Energy Information Administration (“EIA”) shows that residential electricity prices increased between approximately 28% and 40% across five of Zeo’s markets—Pennsylvania, Ohio, Virginia, Florida and Texas—between 2021 and 2025, exceeding the 26.6% national increase. Pennsylvania experienced the largest increase among these states, with average residential electricity prices rising from 13.76 cents to 19.30 cents per kilowatt-hour. These increases have expanded the potential savings available to homeowners whose contracted solar costs have risen more slowly than utility rates.

Residential Electricity Price Increases, 2021–2025

Market 2021 2025 Change  
Pennsylvania 13.76¢ 19.30¢ +40.3%  
Ohio 12.77¢ 16.96¢ +32.8%  
Florida 11.90¢ 15.24¢ +28.1%  
Virginia 11.96¢ 15.28¢ +27.8%  
Texas 12.11¢ 15.47¢ +27.7%  
U.S. average 13.66¢ 17.30¢ +26.6%  
         

Source: U.S. Energy Information Administration, Electricity Data Browser, annual average residential retail price (table and chart).

The EIA expects residential electricity prices to continue rising. In its October 2026 Short-Term Energy Outlook, the agency forecast that the national average residential electricity price would increase from 17.30 cents per kilowatt-hour in 2025 to 18.68 cents in 2027. For the Middle Atlantic region, which includes Pennsylvania, the EIA projected an increase of approximately 13% over the same period.

Unlike utility electricity rates, which fluctuate over time, many residential solar financing arrangements establish predetermined payment schedules, including any annual increases. This structure gives homeowners greater visibility into future electricity costs while allowing the potential savings from solar-generated power to grow when utility rates increase faster than their contracted solar payments.

“Homeowners have historically had little control over what they pay for electricity,” Bridgewater added. “Our approach gives them a clear comparison of their options and the opportunity to secure more predictable energy costs. We’ve built a residential solar business generating more than $70 million in annual revenue, and we believe the growing cost advantage of solar creates opportunities to expand our reach.”

Zeo serves the residential solar market through a vertically integrated platform spanning customer acquisition, system design, permitting, installation and ongoing service. This operating model provides the Company with direct control over key stages of the customer experience as it pursues growth across its target markets.

Savings figures are based on the Company’s analysis of customers whose systems have been in service for three years or more, comparing the cost of power produced by their solar systems with the price of the same power from their utility. Individual results vary based on factors including utility rates, system production, household consumption, financing terms and local net-metering policies. Historical price data are from the EIA Electricity Data Browser; forecasts are from the EIA Short-Term Energy Outlook, October 2026.

About Zeo Energy Corp.

Zeo Energy Corp. (Nasdaq: ZEO) is a diversified energy company providing residential, commercial, industrial and utility-scale solutions designed to reduce energy costs and carbon emissions. Zeo operates Sunergy Solar, a solar, distributed-energy and efficiency-solutions business, and Heliogen, LLC, an energy-generation and long-duration storage business focused on high-demand applications such as data centers and other energy-intensive industries. Through its integrated development, engineering and operating capabilities, Zeo is pursuing opportunities to provide customers with reliable, cost-effective energy solutions across multiple end markets. For more information, visit www.zeoenergy.com.

Cautionary Note Regarding Forward-Looking Statements

This press release and statements of Zeo’s in connection with this press release contain or may contain “forward-looking statements within the meaning of section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Exchange Act of 1934, as amended, that are based on beliefs and assumptions and on information currently available to the Company, including regarding the Company’s involvement or potential involvement in projects. Such statements may include, but are not limited to, statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions. The words “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “explore,” “develop,” “development,” “deploy,” “deployment,” “strategy,” “future,” “likely,” “may,” “should,” “will,” and similar references to future periods may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements may include, for example, statements about the development of projects, future financial performance of the Company; the ability to effectively consolidate the assets of acquired companies and produce expected results; changes in the Company’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects, the ability to raise additional funds, and plans and objectives of management. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts, and assumptions, and involve a number of significant judgments, risks, and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing the Company’s views as of any subsequent date, and the Company does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws. You should not place undue reliance on these forward-looking statements. As a result of a number of known and unknown risks and uncertainties, the Company’s actual results or performance may be materially and adversely different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: (i) planned pipelines and projects may not be developed in the timelines anticipated, if at all; (ii) the outcome of any legal proceedings that may be instituted against the Company or others; (iii) the Company’s success in retaining or recruiting, or changes required in, its officers, key employees, or directors; (iv) the Company’s ability to raise additional capital and maintain the listing of its common stock and warrants on Nasdaq; (v) limited liquidity and trading of the Company’s securities; (vi) geopolitical risk and changes in applicable laws or regulations, including tariffs or trade restrictions; (vii) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (viii) operational risks, including risks associated with Zeo’s expanding business model; (ix) litigation and regulatory enforcement risks, including the diversion of management time and attention and the additional costs and demands on the Company’s resources; (x) the Company’s ability to effectively consolidate the assets of acquired companies and produce the expected results; and (xi) other risks and uncertainties, including those included under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”) for the year ended December 31, 2025 and in its subsequent periodic reports and other filings with the SEC.

In light of the significant risks and uncertainties associated with forward-looking statements, you should not regard these statements as a representation or warranty by the Company, its respective directors, officers or employees or any other person that the Company will achieve its objectives and plans in any specified time frame, or at all. The forward-looking statements in this news release represent the views of the Company as of the date of this news release. Subsequent events and developments may cause that view to change. However, while the Company may elect to update these forward-looking statements at some point in the future, there is no current intention to do so, except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the views of the Company as of any date subsequent to the date of this news release.

Contact:

Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
ZEO@redchip.com

Scientific presentation and patient advocacy engagement follow activation of the first clinical trial site for SOTERIA

PARAMUS, NJ, Nov. 20, 2026 (GLOBE NEWSWIRE) — Polaryx Therapeutics, Inc. (Nasdaq: PLYX) (“Polaryx” or the “Company”), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare pediatric lysosomal storage disorders (LSDs), today highlighted its participation in the 9th NCL Translational Science and Therapeutics Conference and the National Tay-Sachs & Allied Diseases Association’s (NTSAD) Imagine & Believe event in the Boston area. The Company’s participation reflects its commitment to engaging with researchers, clinicians, patient advocates and families as it advances development of its lead investigational drug candidate, PLX-200, across four rare pediatric LSDs.

At the NCL conference, held November 11–13, 2026, at the Marriott Boston Quincy in Quincy, Massachusetts, Will Charlton, M.D., M.A.S., Polaryx Therapeutics’ Chief Medical Officer, presented an update on the Company’s development program, including previously published preclinical findings in a CLN3 mouse model. His presentation took place on Friday, November 13, as part of the session titled, “Clinical Program Updates II: Small Molecules, ERTs and Other Therapeutic Approaches.”

Polaryx was also represented by Shrijay Vijayan, Ph.D. MBA, Chief Scientific Officer, and Minsu Kang, Ph.D., Vice President of Clinical Development and Regulatory Affairs and the conference brought together scientists, clinicians, industry representatives and patient advocacy organizations focused on advancing research and therapeutic development for neuronal ceroid lipofuscinoses (NCLs), commonly known as Batten disease. CLN2 and CLN3 disease are among the four indications being evaluated in Polaryx’s SOTERIA Phase 2 basket trial of orally administered PLX-200.

“Advancing therapies for rare pediatric diseases requires close engagement with the scientific community and the families whose lives are affected by these conditions,” said Alex Yang, Polaryx Therapeutics’ Chair and Chief Executive Officer. “Following activation of our first SOTERIA clinical trial site, these events provided an important opportunity to share our development progress and reinforce our commitment to the patient communities we aim to serve. We remain focused on translating our research into carefully conducted clinical studies that can help address the significant unmet needs of children and families living with these devastating diseases.”

Members of the Polaryx team also attended NTSAD’s Imagine & Believe dinner on November 12, 2026, at the Hyatt Regency Boston/Cambridge. Polaryx supported the event as a sponsor. The annual fundraiser brings together families, researchers, industry representatives and advocates to support research, family services and advocacy for Tay-Sachs, Canavan, GM1 and Sandhoff diseases. Sandhoff disease is also one of the four indications included in SOTERIA.

Polaryx recently announced activation of the first SOTERIA clinical trial site at Boys Town National Research Hospital in Nebraska. SOTERIA is designed to evaluate the safety, tolerability, pharmacokinetics and clinical activity of PLX-200 in children with CLN2 disease, CLN3 disease, Krabbe disease and Sandhoff disease.

About the SOTERIA Trial

SOTERIA is a Phase 2, open-label, single arm trial intended to assess the safety, tolerability, and clinical activity of Polaryx’s lead drug candidate, PLX-200, in CLN2, CLN3, Krabbe disease, and Sandhoff disease, four different LSDs whose patient populations Polaryx believes represent approximately one quarter of the LSD population. SOTERIA is designed to be flexible, resource-efficient, and provide important data and information important to PLX-200’s future clinical development.  Polaryx received a safe to proceed letter in October 2025 from the FDA and plans to initiate SOTERIA in the fourth quarter of 2026 in trial sites in the United States as well as in Europe and Asia or other foreign jurisdictions. Designed with a high degree of flexibility, SOTERIA represents a resource-efficient opportunity to validate PLX-200’s preclinical science across multiple LSDs while gathering data to inform planning PLX-200’s future development pathway, including the initiation of potentially pivotal trials. For the CLN2 and CLN3 cohorts, although the entire trial is open label, these cohorts will incorporate analyses comparing natural history data as a control arm to PLX-200’s treated arm. A natural history study is a preplanned observational study intended to track the course of the disease. Should the data demonstrate compelling clinical activity, Polaryx may pursue an expedited approval pathway. For more information about the SOTERIA trial, please visit https://clinicaltrials.gov/study/NCT07740512.

About Polaryx Therapeutics

Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing patient-friendly small molecule and gene therapy treatments for rare orphan lysosomal storage disorders (LSDs). Founded in 2014, Polaryx seeks to deliver safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs. Our small molecule drug candidates share similar modes of action that have been demonstrated to address lysosomal dysfunction, neuroinflammation, and neuronal loss in our validated animal models that closely mimic human clinical phenotypes. Our most advanced product candidate, PLX-200, targets several LSDs and we intend to launch SOTERIA, a Phase 2 basket trial, to evaluate PLX-200’s safety and efficacy in the fourth quarter of 2026. For more information about the SOTERIA trial, please visit https://clinicaltrials.gov/study/NCT07740512. More information about Polaryx may be found at www.polaryx.com.

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, statements regarding: Polaryx’s clinical development plans for its product candidates, including PLX-200; the timing for initiation of the SOTERIA trial; and potential benefits of PLX-200. Words such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “develop,” “plan” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Polaryx believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Polaryx’s filings with the U.S. Securities and Exchange Commission (the SEC)), many of which are beyond the Company’s control and subject to change. Actual results could be materially different. Risks and uncertainties include: global macroeconomic conditions and related volatility, expectations regarding the initiation, progress, and expected results of Polaryx’s clinical trials; expectations regarding the timing, completion and outcome of Polaryx’s clinical trials; the timing or likelihood of regulatory filings and approvals; liquidity and capital resources; and other risks and uncertainties identified in Polaryx’s most recent Form 10-K, Quarterly Reports on Form 10-Q, and other filings with the SEC. Polaryx claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. Polaryx expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.

Media Contact:
CORE IR
(212) 655-0924
media@polaryx.com

Investor Contact:
CORE IR
(212) 655-0924
investor@polaryx.com

Findings point to a possible blood-based approach for studying CTE in living people

FREMONT, Calif., Nov. 20, 2026 (GLOBE NEWSWIRE) — Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced new research published in the Journal of the American Medical Association (JAMA). Researchers at Boston University CTE Center, with collaborators at Banner Health and more than 20 Institutions, used Alamar’s NULISAqpcr™ eMTBR-tau single-plex assay to evaluate whether a blood test could identify chronic traumatic encephalopathy (CTE) pathology in living patients.

The researchers found higher blood levels of eMTBR-tau in former football players with advanced CTE and that levels rose with the amount of tau tangle pathology in the brain. eMTBR-tau is a protein fragment linked to the tau tangles seen in CTE and Alzheimer’s disease. CTE is a. neurodegenerative disease associated with repeated head impacts. Today it can only be confirmed by examining the brain after death. The finding could give researchers a way to study CTE during life.

“CTE has been extraordinarily difficult to study because doctors cannot confirm it in a living person. Proteins like eMTBR-tau have recently been associated with neuropathology but are present at very low levels in blood,” said Yuling Luo, PhD, founder, CEO and chair of Alamar Biosciences. “Our NULISA technology was built to measure low abundant proteins, and a reliable, simple blood test for CTE would enable new research into the progression and treatment of this debilitating illness. There is more work to do, but studies like this one show why that effort matters.”

The study included 21 former American football players who gave blood samples during life and later donated their brains for research through Boston University CTE Center Studies. Eighteen had CTE, including 16 with high-stage disease. Plasma eMTBR-tau was significantly higher in high-stage CTE than in low-stage CTE or no CTE. Five of the CTE cases also had Alzheimer’s disease, and eMTBR-tau levels were highest in people who had both conditions. The researchers also measured p-tau217, an established blood marker for Alzheimer’s disease. It was elevated only in people with Alzheimer’s pathology and was not associated with CTE. Used together, the two markers may help researchers tell the conditions apart.

The study suggests a promising new biomarker approach to accurately detecting CTE pathology through a blood test, with the potential to improve patient diagnosis, identification and enrollment in clinical trials, and support the development of targeted therapies. The researchers describe the results as an early study that requires validation in larger and diverse cohorts. The test is not a diagnostic tool and is not available for clinical use. To date, no blood test has yet been validated for diagnosing CTE in living patients.

“Having blood tests that accurately determine the underlying pathology, which are now approved for use in Alzheimer’s disease, has been revolutionary in the way we diagnose patients and design therapeutic trials,” said Nicholas Ashton, PhD, co-senior author of the study and senior director of Banner Health’s Fluid Biomarker Program. “With this new study, we are optimistic this biomarker will spur a serious discussion about treatment development for CTE.”

Dr. Ashton’s work also includes blood-based eMTBR-tau measurement in Alzheimer’s disease, most recently in a JAMA study published November 16 that used a NULISA-based assay to assess tau pathology in plasma from 728 research participants.

About Alamar Biosciences

Alamar is a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Leveraging our proprietary NULISA™ technology and the ARGO® HT System, our platform is designed to detect protein biomarkers at extremely low concentrations in blood with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, helping researchers unlock the full spectrum of protein biomarkers across disease states. Learn more at alamarbio.com.

Forward Looking Statements

This press release may contain forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding Alamar’s NULISA platform’s capabilities, performance and impact on CTE research on live patients. Any forward-looking statements in this press release are based on Alamar Biosciences’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Readers are cautioned that actual results could differ materially from those expressed or implied in Alamar Biosciences’ forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to intense competition in the proteomics market, exposure to legal proceedings, regulatory inquiries and other legal matters, failure to develop new assays or instruments, dependence on researchers who rely heavily on government funding, reductions in spending by research and academic institutions, the potential for products to be subject to more onerous regulation by the FDA or other regulatory requirements, the complexity of manufacturing Alamar Biosciences’ instruments and consumables, failure to obtain marketing authorizations for future products that are intended for clinical or diagnostic use, Alamar Biosciences’ ability to protect its intellectual property, and the other risks described in Alamar Biosciences’ filings with the U.S. Securities and Exchange Commission, including its Quarterly Report on Form 10-Q filed with the SEC on August 11, 2026. Alamar Biosciences explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Media Contact:
Media@alamarbio.com

Investor Contact:
Investors@alamarbio.com

Aspo Plc Stock Exchange Release 20 November 2026 at 15.00 EET

Aspo publishes the demerger and listing prospectus of ESL Shipping Group Plc, which has been approved by the Finnish Financial Supervisory Authority

The Finnish Financial Supervisory Authority has approved the Finnish-language demerger and listing prospectus of ESL Shipping Group Plc (“ESL Shipping”), to be incorporated in the demerger. Aspo Plc (“Aspo”) has prepared and published the demerger and listing prospectus on behalf of ESL Shipping for the purposes of issuing the demerger consideration to the shareholders of Aspo and of applying for the shares in ESL Shipping to be admitted to trading on the regulated market operated by Nasdaq Helsinki Ltd.

The Board of Directors of Aspo approved and signed the demerger plan on 3 August 2026. The Board of Directors of Aspo has proposed that the Extraordinary General Meeting of Aspo to be held on 7 December 2026 would approve the demerger plan and resolve on the partial demerger of Aspo in accordance with the demerger plan.

The Finnish-language demerger and listing prospectus approved by the Finnish Financial Supervisory Authority will be available no later than 23 November 2026 on Aspo’s website at aspo.com/fi/jakautuminen, and an unofficial English translation thereof will be available at aspo.com/demerger. The demerger and listing prospectus contains more detailed information on the demerger and ESL Shipping.

Aspo Plc
Board of Directors


Further information

Rolf Jansson, CEO, Aspo Plc, tel. +358 400 600 264, rolf.jansson@aspo.com

Heikki Westerlund, Chair of the Board of Directors, Aspo Plc, heikki@heiwes.com

Distribution:
Nasdaq Helsinki
Key media
www.aspo.com

About Aspo

Aspo creates value by owning and developing business operations sustainably and in the long term. Aspo’s businesses – ESL Shipping and Telko – enable future-proof, sustainable choices for customers in various industries. Established in 1929, today we are together about 650 experts on land and at sea. While the Nordic region is our core market, we serve our customers with world-class solutions in 18 countries around Europe and parts of Asia.

Aspo is listed on Nasdaq Helsinki and is headquartered in Finland.

Aspo – Sustainable value creation

Important notice

This release does not constitute a notice to convene a general meeting of shareholders nor does it constitute a demerger and listing prospectus. Any decision with respect to the proposed partial demerger of Aspo should be made solely on the basis of the information contained in Aspo’s notice to convene the general meeting of shareholders and the demerger and listing prospectus, as well as on an independent assessment of the information contained therein. Investors are directed to consult the demerger and listing prospectus for more comprehensive information on ESL Shipping, its shares and the proposed demerger.

This release does not constitute an offer of securities for sale or a solicitation of an offer to subscribe or purchase any securities described in such release in the United States. In particular, any securities referred to in this release have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act“), or with any regulatory authority of any state or other jurisdiction in the United States, and may not be offered, sold, transferred or delivered, directly or indirectly, in or into the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with applicable state and other securities laws. There will be no public offering of securities in the United States.

The shares in ESL Shipping have not been and will not be listed on a U.S. securities exchange or quoted on any inter-dealer quotation system in the United States. Neither Aspo nor ESL Shipping intends to take any action to facilitate a market in the shares in ESL Shipping in the United States. Consequently, it is unlikely that an active trading market in the United States will develop for the shares in ESL Shipping.

The shares in ESL Shipping have not been approved or disapproved by the U.S. Securities and Exchange Commission, any state securities commission or any other regulatory authority in the United States, nor have any of the foregoing authorities passed comment upon, or endorsed the merit of, the partial demerger or the accuracy or adequacy of this release. Any representation to the contrary is a criminal offence in the United States.

This release is for information purposes only and is not intended to and does not constitute or form part of any offer or invitation to purchase, otherwise acquire, subscribe for, sell, otherwise dispose of or issue, or any solicitation of any offer to sell, otherwise dispose of, issue, purchase, otherwise acquire or subscribe for, any security. This communication is directed only at persons who are outside the United Kingdom or persons who are qualified investors within the meaning of the Public Offers and Admissions to Trading Regulations 2024 and are also (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order“) or (ii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2) of the Order (all such persons together being referred to as “Relevant Persons“). Any investment activity to which this communication relates will only be available to, and will only be engaged with, Relevant Persons. Any person who is not a Relevant Person should not act or rely on this document or any of its contents.

Forward-looking statements

This release includes “forward-looking statements” that are not historical facts but are based on present plans, estimates, projections and expectations and are not guarantees of future performance. Words such as “intend”, “assess”, “expect”, “may”, “plan”, “believe”, “estimate” and other expressions entailing indications or predictions of future developments or trends, not on historical facts, constitute forward-looking statements. They are based on certain expectations and assumptions, which, even though they seem to be reasonable at present, may turn out to be incorrect. Shareholders should not rely on these forward-looking statements. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors because they relate to events and depend on circumstances that may or may not occur in the future. Numerous factors may cause the actual results of operations or financial condition of Aspo or ESL Shipping to differ materially from those expressed or implied in the forward-looking statements. Neither Aspo, ESL Shipping, nor any of their affiliates, advisors or representatives or any other person undertakes any obligation to review, confirm or to release publicly any updates or revisions to any forward-looking statements to reflect events that occur or circumstances that arise after the date of this release other than as required by applicable laws and regulations.

TULIKIVI CORPORATION  STOCK EXCHANGE RELEASE  20 NOVEMBER 2026 3:00 PM

Tulikivi Corporation financial reporting in 2027

Tulikivi Corporation will publish its 2026 Financial Statements Release on 5 March 2027. The Annual Report will be published on the company’s website during the week starting on 22 March 2027. The Annual General Meeting will be held on 22 April 2027.

The following reports will be published in 2027:
– Interim Report for January–March 7 May 2027
– Half Year Financial Report for January–June 13 August 2027
– Interim Report for January–September 5 November 2027

TULIKIVI CORPORATION
Board of Directors
Further information: Heikki Vauhkonen, Managing Director, tel. +358 40 524 5593
Distribution: Nasdaq Helsinki, key media

www.tulikivigroup.com

MCLEAN, Va., Nov. 20, 2026 (GLOBE NEWSWIRE) — Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a healthcare technology, data, and insights company, today announced that members of its management team will meet with investors at the following events in December 2026:

  • BofA Securities Leveraged Finance Conference – Tuesday, December 1, 2026, at the Boca Raton – Presentation at 7:30 a.m. ET and small group meetings
  • Piper Sandler 38th Annual Healthcare Conference – Thursday, December 3, 2026, at the Lotte New York Palace – Fireside chat at 12:00 p.m. ET and one-on-one meetings

A live webcast and audio archive of the events will be available through the investor relations section of Claritev’s website at https://investors.claritev.com/. For one-on-one meetings, please contact a representative at the host firms.

About Claritev

Claritev is a healthcare technology, data, and insights company focused on delivering affordability, transparency, and quality across the U.S. healthcare system. Led by deeply experienced associates, data scientists, and innovators, Claritev provides technology-enabled solutions fueled by decades of claims expertise. The company leverages advanced analytics and AI to power a robust enterprise platform that delivers clear, actionable insights to support affordability, price transparency, and optimized network and benefits design. By supporting key stakeholders, including payers, employers, patients, providers, and third parties, Claritev is dedicated to making healthcare more accessible and affordable for all.

Claritev serves more than 750 healthcare payers, over 100,000 employers, 60 million consumers, and 1.4 million contracted providers. For more information, visit claritev.com.

Investor Relations Contacts
Todd Friedman
Head of Investor Relations and Strategic Communications
Claritev
investor@claritev.com

Media Relations Contact
Jen O’Connor
VP, Brand Marketing
Claritev
press@claritev.com

Source: Claritev Corporation

VANCOUVER, Canada, Nov. 20, 2026 (GLOBE NEWSWIRE) — Sonoro Gold Corp. (TSXV: SGO | OTCQB: SMOFF | FRA: 23SP) (“Sonoro” or the “Company”) is pleased to announce the completion of a comprehensive geotechnical investigation program and the commencement of advanced engineering for a proposed open pit, mining operation at its Cerro Caliche gold project in Sonora, Mexico.

The Company engaged BBA Consultants International LP (“BBA”) to oversee geotechnical investigations and develop the feasibility-level engineering design for the proposed heap leach facility as part of the overall feasibility study, with Ausenco Mexico S. de R.L. de C.V. (“Ausenco”) serving as the lead engineering consultant for the overall project. The extensive geotechnical and geophysical investigations have now been completed with advanced engineering and the HLF design expected to be finalized by the end of Q1 in 2027.

The programs mark important advancements of Cerro Caliche and are expected to provide key technical inputs for project design, development planning, and ongoing permitting activities.

“The geotechnical investigations and advanced engineering are fundamental to both the design criteria and structural integrity of the proposed Cerro Caliche operation,” said Kenneth MacLeod, President and CEO. “This work reflects additional de-risking milestones at Cerro Caliche while we continue with our very successful drilling program which has identified higher-grade mineralization at the recently acquired Diana and Batamote concessions.”

Geotechnical Investigation Programs
BBA coordinated and provided technical oversight of the geotechnical and geophysical investigation programs conducted by specialized third-party contractors to support the feasibility-level engineering design of the proposed heap leach facility. The investigations covered the proposed heap leach pad, solution ponds, crushing plant, ancillary facilities, waste rock area, and other areas across the project site. Field activities included geophysical surveys, borehole drilling, test pit excavations, and piezometer installations.

Eight HQ-size geotechnical boreholes were completed to characterize subsurface soil and bedrock conditions. In addition, 16 test pits were excavated to depths ranging from 1.40 to 5.80 meters.

Onsite Standard Penetration Tests (SPT) were carried out in the soil intervals and permeability testing to evaluate the hydraulic conditions and laboratory testing was conducted on soil and rock samples taken from the boreholes and pits to adequately characterize foundation soils.

The results and details from the site work are being used for the final heap leach design to a feasibility level with full details of water balance, material take-offs of the liner system and water diversion requirements.

The geotechnical results are expected to be instrumental for project development and are currently being utilized as key inputs into the advanced engineering phase currently underway.

Advanced Engineering 
Advanced engineering is being led by Ausenco Mexico, a global engineering, consultancy and project delivery company specializing in the mining and metals industry.

The scope of work is to further define key components of the proposed mining operation, incorporating the results of recent geotechnical work, as well as environmental and engineering studies completed across the project site.

The engineering work is expected to provide additional detail regarding site infrastructure, operational design criteria, construction requirements, and implementation planning for the development, construction and commissioning of the process facilities.

Qualified Person Statement
Stephen Kenwood, P.Geo., an Independent Director of Sonoro Gold Corp., is a Qualified Person as defined in National Instrument 43-101 (NI 43-101) and has reviewed and approved the scientific and technical information contained in this news release.

About BBA Consultants
BBA has been providing a wide range of consulting engineering services for over 45 years. Strategic advisory, environmental, engineering and field experts team up to quickly and accurately pinpoint the needs of industrial and institutional clients. Known for its innovative, sustainable and reliable solutions, the firm’s expertise is recognized in the energy and natural resources industry. BBA has over 30 plus offices across Canada and abroad (Chile, Peru and the United States), offering clients local support and increased field presence.

About Ausenco
Ausenco is a global engineering, consulting, and project delivery company built for the minerals and metals industry. With more than three decades of global experience, we partner with clients to navigate complex challenges from initial study through final closure, across all project phases and on five continents. Drawing on deep roots in the minerals and metals sector, our team combines technical expertise, practical experience, and proven insights to deliver innovative, pragmatic solutions that reduce risk and create value.

About Sonoro Gold Corp.
Sonoro Gold Corp. is a publicly listed exploration and development Company holding the near-development-stage Cerro

Caliche project and the exploration-stage San Marcial project in Sonora State, Mexico. The Company has highly experienced operational and management teams with proven track records for the discovery and development of natural resource deposits.

To keep up-to-date on Sonoro’s developments, please join our online communities on X, Facebook, LinkedIn, Instagram, and YouTube and visit Sonoro’s website and subscribe to receive the latest news and updates delivered straight to your inbox.

On behalf of the Board of Sonoro Gold Corp.
Per:        “Kenneth MacLeod”
                Kenneth MacLeod
                President & CEO

For further information, please contact: 
Sonoro Gold Corp. – Tel: (604) 632-1764
Email: info@sonorogold.com

Forward-Looking Statement Cautions:
This press release may contain “forward-looking information” as defined in applicable Canadian securities legislation. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the Cerro Caliche project, and future plans and objectives of the Company, constitute forward looking information that involve various risks and uncertainties, including statements regarding completion of an updated preliminary economic assessment of the Cerro Caliche Gold project.. Although the Company believes that such statements are reasonable based on current circumstances, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “aims”, “potential”, “goal”, “objective”, “prospective” and similar expressions, or that events or conditions “will”, “would”, “may”, “can”, “could” or “should” occur, or are those statements, which, by their nature, refer to future events.  The Company cautions that forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made and they involve a number of risks and uncertainties, including the possibility of unfavorable exploration and test results, the lack of sufficient future financing to carry out exploration and development plans and unanticipated changes in the legal, regulatory and permitting requirements for the Company’s exploration programs.  There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law or the policies of the TSX Venture Exchange. Readers are encouraged to review the Company’s complete public disclosure record on SEDAR at www.sedar.com.

This press release does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein have not been and will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), or with any securities regulatory authority of any state or other jurisdiction in the United States, and may not be offered or sold, directly or indirectly, within the United States or to, or for the account or benefit of, U.S. persons, as such term is defined in Regulation S under the Securities Act (“Regulation S”), except pursuant to an exemption from or in a transaction not subject to the registration requirements of the Securities Act”


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.